Healthcare Stocks: Value Trap or Generational Buy?
Episode publishedPodcast: Lumida Wealth : Non-Consensus...Lumida Wealth : Non-Consensus Invest Beyond the Ordinary
Transcript preview
Preview only
Welcome to nonconsensus investing. I'm Ram Alawwalia, your host and CIO at Lumida Wealth, where we specialize in the craft of alternative investments. At Lumida, we help guide clients through the intricacies of managing wealth so they don't have to shoulder the burden alone. Through this podcast, we draw back the curtain to reveal the strategies employed by the best in the business for their clients so that you too can invest beyond the ordinary. Good afternoon, and we are live with the next episode of Lumida nonconsensus investing. I am Ram Alawwalia, your host and chief investment officer at
Hey, Rob. I'm fine. How are you?
Good. Good. We first met, I think it was two years ago, at the Coin Miami conference that our mutual friend David Bailey puts on.
Yeah. You were saying a lot of really smart things about the Grayscale ETF. I remember
that guy. Well,
I wanna go. That guy.
That was a those was a long time ago. I remember when I was speaking to you, we were talking about biotech investing, and ten plus years ago, I used to allocate to hedge funds, and you had done the same. And you also had invested in the same funds. We won't talk about those funds now. It's ten years later. The world's changed. Different kind of opportunity set. But I remember saying, oh, wow. Like, Avik is super sharp, really enjoyed the conversation. And here we are. We're gonna try to solve all of health care's problems in the next forty five minutes or so. Alright. Amazing. That should be f
Yeah. There's a bunch of things happening in the and we're talking specifically about the insurers now, managed care. For those of your listeners and viewers who spend a lot of time in this space, they'll be aware that the vast majority of the equity market cap in health care is pharma and biotech. Let's say 10%, ten, fifteen percent is nontherapeutics. But managed care is the big is certainly a big chunk of the nontherapeutic market cap in health care. And the managed care stocks have generally been hammered, and not just the stocks, by the way. If you look at the the nonprofit Blue Cross pla
Like reimbursement coding roadblocks that compensates All
Keep exploring with a free account.
A free account preserves the short preview. Upgrade to Pro for the full transcript and episode chat.